The TICS showed consistent prognostic effects across the prostate cancer patients with different clinicopathological characteristics (e.g., TNM stage, pre-treatment prostatic specific antigen [PSA], and Gleason score) and this score was an independent prognostic factor of BCRFS. The gene discussed is KLK3; the disease is Familial prostate cancer.